Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:OPTNNASDAQ:RAPPNASDAQ:RGNXNASDAQ:STOK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeOPTNOptiNose$9.10-0.4%$6.56$4.82▼$21.15$91.66M-0.8864,610 shs229,502 shsRAPPRapport Therapeutics$8.99+5.5%$12.13$6.43▼$29.74$328.10MN/A178,226 shs343,370 shsRGNXREGENXBIO$6.29-5.7%$7.30$5.62▼$19.88$315.04M1.26772,322 shs1.09 million shsSTOKStoke Therapeutics$5.94-5.7%$8.94$5.66▼$17.58$321.22M1.09719,339 shs1.15 million shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceOPTNOptiNose-0.44%-0.55%+67.28%+40.00%-56.04%RAPPRapport Therapeutics+5.52%-10.55%-14.14%-53.85%+898,999,900.00%RGNXREGENXBIO-5.70%-19.67%+0.64%-19.05%-68.94%STOKStoke Therapeutics-5.71%-17.61%-27.21%-48.30%-53.65%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationOPTNOptiNose2.6594 of 5 stars1.03.00.04.22.92.50.6RAPPRapport Therapeutics1.5522 of 5 stars3.50.00.00.02.31.70.6RGNXREGENXBIO4.401 of 5 stars4.42.00.04.61.32.51.3STOKStoke Therapeutics3.2414 of 5 stars3.60.00.04.82.11.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceOPTNOptiNose 2.00Hold$9.00-1.10% DownsideRAPPRapport Therapeutics 3.00Buy$35.00289.32% UpsideRGNXREGENXBIO 2.86Moderate Buy$32.78421.11% UpsideSTOKStoke Therapeutics 3.13Buy$24.67315.26% UpsideCurrent Analyst Ratings BreakdownLatest OPTN, RAPP, STOK, and RGNX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/21/2025OPTNOptiNosePiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Neutral$15.00 ➝ $9.003/21/2025OPTNOptiNoseHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$18.00 ➝ $9.003/20/2025OPTNOptiNosePiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold3/20/2025OPTNOptiNoseLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold$17.00 ➝ $9.003/20/2025RGNXREGENXBIOChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$52.00 ➝ $52.003/19/2025STOKStoke TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$47.00 ➝ $47.003/19/2025STOKStoke TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$24.00 ➝ $24.003/18/2025RGNXREGENXBIOLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$24.003/18/2025STOKStoke TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.00 ➝ $22.003/17/2025RGNXREGENXBIOHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$36.00 ➝ $34.003/14/2025RGNXREGENXBIOMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$22.00 ➝ $24.00(Data available from 4/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookOPTNOptiNose$78.23M1.17N/AN/A($11.56) per share-0.79RAPPRapport TherapeuticsN/AN/AN/AN/AN/AN/ARGNXREGENXBIO$83.33M3.78N/AN/A$7.09 per share0.89STOKStoke Therapeutics$36.56M8.79N/AN/A$3.57 per share1.66Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateOPTNOptiNose-$35.48M-$2.88N/AN/AN/A-41.16%N/A-27.42%5/13/2025 (Estimated)RAPPRapport Therapeutics-$34.79M-$13.84N/AN/AN/AN/AN/AN/A6/2/2025 (Estimated)RGNXREGENXBIO-$263.49M-$4.61N/AN/AN/A-283.19%-70.65%-41.68%5/6/2025 (Estimated)STOKStoke Therapeutics-$104.70M-$1.68N/AN/AN/A-629.90%-54.45%-40.77%5/5/2025 (Estimated)Latest OPTN, RAPP, STOK, and RGNX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/26/2025Q4 2024OPTNOptiNose-$0.70-$0.03+$0.67-$0.03$21.02 million$21.47 million3/24/2025Q4 2024STOKStoke Therapeutics-$0.56-$0.18+$0.38-$0.18$4.20 million$22.61 million3/13/2025Q4 2024RGNXREGENXBIO-$1.27-$1.01+$0.26-$1.01$23.70 million$21.21 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthOPTNOptiNoseN/AN/AN/AN/AN/ARAPPRapport TherapeuticsN/AN/AN/AN/AN/ARGNXREGENXBION/AN/AN/AN/AN/ASTOKStoke TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioOPTNOptiNoseN/A0.790.72RAPPRapport TherapeuticsN/A45.9145.91RGNXREGENXBION/A3.053.05STOKStoke TherapeuticsN/A5.095.09Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipOPTNOptiNose85.60%RAPPRapport TherapeuticsN/ARGNXREGENXBIO88.08%STOKStoke TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipOPTNOptiNose2.30%RAPPRapport TherapeuticsN/ARGNXREGENXBIO13.13%STOKStoke Therapeutics11.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableOPTNOptiNose19010.07 million9.83 millionNot OptionableRAPPRapport TherapeuticsN/A36.50 millionN/AN/ARGNXREGENXBIO37050.09 million43.04 millionOptionableSTOKStoke Therapeutics10054.08 million46.98 millionOptionableOPTN, RAPP, STOK, and RGNX HeadlinesRecent News About These CompaniesStoke Therapeutics to Present at the 24th Annual Needham Virtual Healthcare ConferenceApril 1, 2025 | businesswire.comStoke Therapeutics remains significantly undervalued, says CanaccordApril 1, 2025 | markets.businessinsider.comResearch Analysts Set Expectations for STOK FY2025 EarningsMarch 29, 2025 | americanbankingnews.comWhat is Chardan Capital's Forecast for STOK FY2025 Earnings?March 28, 2025 | marketbeat.comCantor Fitzgerald Issues Positive Forecast for STOK EarningsMarch 24, 2025 | marketbeat.comEarnings Beat: Stoke Therapeutics, Inc. (NASDAQ:STOK) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their ForecastsMarch 22, 2025 | finance.yahoo.comWhat is HC Wainwright's Forecast for STOK Q3 Earnings?March 22, 2025 | marketbeat.comLeerink Partnrs Weighs in on STOK Q1 EarningsMarch 22, 2025 | marketbeat.comQ1 EPS Estimate for Stoke Therapeutics Lifted by AnalystMarch 22, 2025 | marketbeat.comStoke Therapeutics, Inc. (NASDAQ:STOK) Given Consensus Recommendation of "Buy" by BrokeragesMarch 22, 2025 | marketbeat.comInsider Selling: Stoke Therapeutics, Inc. (NASDAQ:STOK) General Counsel Sells 2,266 Shares of StockMarch 21, 2025 | marketbeat.comInsider Selling: Stoke Therapeutics, Inc. (NASDAQ:STOK) Insider Sells 3,884 Shares of StockMarch 21, 2025 | marketbeat.comInsider Selling: Stoke Therapeutics, Inc. (NASDAQ:STOK) Director Sells 10,382 Shares of StockMarch 21, 2025 | marketbeat.comEquities Analysts Offer Predictions for STOK Q1 EarningsMarch 21, 2025 | marketbeat.comStoke Therapeutics, Inc. (NASDAQ:STOK) General Counsel Jonathan Allan Sells 2,266 SharesMarch 21, 2025 | insidertrades.comStoke Therapeutics' (STOK) Buy Rating Reiterated at HC WainwrightMarch 20, 2025 | marketbeat.comStoke Therapeutics' (STOK) "Buy" Rating Reiterated at Chardan CapitalMarch 20, 2025 | marketbeat.comThe Escalator: Stoke Therapeutics, Merck, Sutro Biopharma and moreMarch 19, 2025 | mmm-online.comNeedham & Company LLC Reaffirms "Buy" Rating for Stoke Therapeutics (NASDAQ:STOK)March 19, 2025 | marketbeat.comStoke Therapeutics (NASDAQ:STOK) Posts Quarterly Earnings Results, Beats Expectations By $0.38 EPSMarch 19, 2025 | marketbeat.com2STOK : Forecasting The Future: 7 Analyst Projections For Stoke TherapeuticsMarch 19, 2025 | benzinga.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWarren Buffett Swaps VOO for This Reliable Dividend StockBy Sarah Horvath | March 7, 2025View Warren Buffett Swaps VOO for This Reliable Dividend StockNVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a BuyBy Thomas Hughes | March 12, 2025View NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a BuyBYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?By Jeffrey Neal Johnson | March 21, 2025View BYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?Broaden Your ETF Exposure With These 3 Overlooked FundsBy Nathan Reiff | March 6, 2025View Broaden Your ETF Exposure With These 3 Overlooked FundsRecession Risk: Is It Going to Happen? Here Are the Key CluesBy Jea Yu | March 26, 2025View Recession Risk: Is It Going to Happen? Here Are the Key CluesOPTN, RAPP, STOK, and RGNX Company DescriptionsOptiNose NASDAQ:OPTN$9.10 -0.04 (-0.44%) Closing price 04/4/2025 04:00 PM EasternExtended Trading$9.10 +0.01 (+0.05%) As of 04/4/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.Rapport Therapeutics NASDAQ:RAPP$8.99 +0.47 (+5.52%) Closing price 04/4/2025 04:00 PM EasternExtended Trading$9.01 +0.02 (+0.17%) As of 04/4/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON.REGENXBIO NASDAQ:RGNX$6.29 -0.38 (-5.70%) Closing price 04/4/2025 04:00 PM EasternExtended Trading$6.30 +0.01 (+0.16%) As of 04/4/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.Stoke Therapeutics NASDAQ:STOK$5.94 -0.36 (-5.71%) Closing price 04/4/2025 04:00 PM EasternExtended Trading$5.94 0.00 (0.00%) As of 04/4/2025 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Archer Aviation’s Africa Deal Could Boost ACHR Stock The Ecosystem Edge: Joby's Competitive Advantage Intel’s Big Bet on 18A: Will Lip-Bu Tan’s Vision Pay Off? Lamb Weston Stock Rises, Earnings Provide Calm Amidst Chaos Sportsman’s Warehouse Trading Volume Spike Signals Opportunity Broadcom’s VMware Strategy Could Fuel the Next AVGO Rally Arm Holdings Aims for 50% Data Center Market Share Cathie Wood Loads Up on Baidu—Is It the Right Time to Buy? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
